CJC-1295 / Ipamorelin Stack vs MGF
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profileMGF
MGF (Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical loading (exercise, especially eccentric loading). Unlike circulating IGF-1 which is produced primarily by the liver, MGF is generated within the muscle itself and acts locally to activate satellite cells (muscle stem cells) — the cells responsible for muscle repair, growth, and adaptation. It is considered the primary local anabolic signal generated by resistance training.
Full profile| CJC-1295 / Ipamorelin Stack | MGF | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination | Mechano Growth Factor, IGF-1Ec, Insulin-like Growth Factor splice variant |
| Evidence | FDA-approved | Preclinical only |
| Dosing range | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) | 100mcg–300mcg mcg, Post-workout (within 30–60 minutes of training), 3–4x weekly |
| Administration | Subcutaneous injection (both compounds), Administered together in the same injection | Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution) |
| Key side effects | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) | Localized muscle swelling at injection site (normal response), Hypoglycemia (less pronounced than IGF-1 DES but present), Very short half-life means side effects are brief, Potential overuse injury if post-workout injection is used consistently without adequate recovery |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while MGF is preclinical only.
- Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; MGF — Intramuscular injection (into worked muscle — critical for local effect), Subcutaneous injection (produces more systemic distribution).
- Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); MGF is Post-workout (within 30–60 minutes of training), 3–4x weekly.
- Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 3 for MGF.
How each works
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
MGF
MGF is encoded by the IGF-1 gene but produced via alternative splicing that generates a unique 49-amino acid C-terminal E-peptide (Ec peptide). The Ec peptide has distinct biological activity from the IGF-1 domain — it directly activates satellite cell proliferation through a receptor pathway separate from the standard IGF-1R. Studies in rodents show that local MGF injection produces significant muscle hypertrophy in the injected limb without systemic IGF-1 elevation. MGF expression spikes within 30 minutes of resistance exercise and declines over 24–48 hours — aligning precisely with the post-exercise anabolic window.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.